0
The German government is contemplating pharmaceutical price control legislation as it battles soaring drug spending. On the one hand Germany is keen to promote the use of generic drugs and generic medicines have already achieved high penetration—75% by volume in 2009. This highlights opportunities for generic manufacturers in Europe's largest, albeit competitive, drug market.
- Home
-
Generics
News
- FDA approves generic teriparatide and levetiracetam
- US generics launch and approval for Dr Reddy’s and Lupin
- Five Chinese companies join UN’s MPP for Covid-19 medicines
- South Korean companies to make generic Bridion and COVID-19 drugs
Research
- Japan’s drug shortage crisis: challenges and policy solutions
- Saudi FDA drug approvals and GMP inspections: trend analysis
- Generic medications in the Lebanese community: understanding and public perception
- Community pharmacists’ understanding of generic and biosimilar drugs: Lebanon case study
-
Biosimilars
News
- Canada approves multiple denosumab and ustekinumab biosimilars as global competition grows
- FDA approves Zimrixby (rituximab) and Garzulys (insulin aspart) biosimilars
- EMA recommends approval for biosimilar pegfilgrastim Cavoley
- FDA approves first interchangeable ranibizumab biosimilar Ranluspec
Research
- HHS push to ‘genericize’ biosimilars sparks backlash
- Biosimilar interchangeability: a necessary fix, but not a silver bullet
- EULAR 2025 RA guidelines streamlined as biosimilar expansion reshapes treatment sequencing
- Biosimilars uptake in Chile: why does it lag behind?
- MORE EDITORIAL SECTIONS
- Search
Post your comment